9888À­Ë¹Î¬¼Ó˹

        °©Ö¢µÄÔçÆÚÕï¶ÏÊÇÈ«ÇòÖ×Áö¿ØÖÆÓëÔ¤·ÀµÄÒªº¦°ì·¨£¬¼°Ôç·¢Ã÷ÓÐÀûÓÚÑ°ÕÒÓÐÓõÄÖÎÁƼƻ®´Ó¶ø½µµÍéæÃüÂÊ¡£ÎªÁËÌá¸ß°©Ö¢»¼ÕßµÄÕï¶ÏЧÂÊ£¬¸ßѸËٶȵÄɸ²éÒªÁìÓÈΪÖ÷Òª¡£

ͼƬȪԴ£ºHum Genomics . 2020 May 6;14(1):15.

Ò»¡¢Ö×Áö±ê¼ÇÎï

        Ö×Áö±ê¼ÇÎïÊÇ°©Ï¸°û»òÌåÄÚÆäËûϸ°ûÏìÓ¦°©Ö¢»òijЩÁ¼ÐÔ¼²²¡£¨·Ç°©ÐÔ£©×´Ì¬¶ø±£´æ»òÓÉÆ䱬·¢µÄÎïÖÊ¡£ËûÃÇÓÉÕý³£Ï¸°ûºÍ°©Ï¸°ûÅäºÏ±¬·¢£¬°©Ï¸°û±¬·¢µÄÁ¿¸ü¸ß£¬¿ÉÓÃÓÚÅбðÖ×ÁöÓë·ÇÖ×Áö»ò¿µ½¡¸öÌå¡£ÕâЩÎïÖʿɱ£´æÓÚÖ×Áöϸ°ûºÍ×éÖ¯ÖУ¬Ò²¿ÉÒÔ½øÈëѪҺºÍÌåÒº£¨ÐØË®¡¢¸¹Ë®¡¢ÄÔ¼¹ÒºµÈ£©ÖУ¬Òò´Ë¿Éƾ֤ÆäѪҺ»òÆäËûÌåÒºÖеIJâ³ö¶ø˼Á¿Ö×ÁöµÄ±£´æ¡£Ëæ×ÅÈ«Çò°©Ö¢¼ç¸ºµÄÖðÄêÔöÌí£¬Ö×Áöѧר¼ÒÃÇÕýÔÚÑ°ÕÒ¾«×¼¡¢Ãô¸ÐµÄ°ÐÏòÖ×Áö¼ì²âÒªÁì²¢¼à²âÆäÉú³¤¡£

        ѪҺÖ×Áö±ê¼ÇÎï¶ÔÖ×ÁöµÄ±£´æ¾ßÓÐÖ÷ÒªµÄÌáÐÑÒâÒ壬ԽÀ´Ô½¶àµÄ³ÉΪÖ×ÁöÔçÆÚÕï¶ÏÑо¿µÄÈÈÃÅÒýÆðÁÙ´²Ò½ÉúµÄ¹Ø×¢¡£½üÄêÀ´£¬ÑªÇåÖ×Áö±ê¼ÇÎïÖð½¥×÷ΪÆäÕï¶Ï¹¤¾ßµÄÒ»²¿·Ö£¬ÆäÖÐѪÇåÐÂÐÍÖ×Áö±ê¼ÇÎï DR-70ÒòÆäÎÞ´´µÈ¼ì²âÓÅÊÆ£¬Öð½¥ÏÔʾ³öÖ÷Òª¼ÛÖµ¡£

        Ö×Áö±ê¼ÇÎïÒ»Á¬ÊÓ²ì¸üÓÐÒâÒ壬ͻȻÉý¸ßÖµµÃ×¢ÖØ£¬¿ÉÊÇÉý¸ßʱ²»¿ÉÈÝÒ×Õï¶ÏΪ¶ñÐÔÖ×Áö£¬ÐèҪ͎áÆäËûÏà¹Ø¼ì²é¡¢ÁÙ´²Ö¢×´¡¢Ìå¸ñ¼ì²éµÈ×ÛºÏÅжÏ¡£

ͼƬȪԴ£ºJournal of Immunoassay and Immunochemistry, 31:131–147, 2010

¶þ¡¢ÑªÇåÐÂÐÍÖ×Áö±ê¼ÇÎïDR-70

        DR-70ΪÏËάÂÑ°×½µ½â¸´ºÏÎÖ×Áöϸ°ûÄܹ»Ôö½øÌåÄÚ×éÖ¯Òò×Ó¡¢ÄýѪÒò×ӵȴÙÄýÒò×ÓµÄÊÍ·Å£¬Ê¹»úÌå´¦ÓÚ¸ßÄý״̬£¬ÏËάÂÑ°×Ô­¼°ÏËάÂÑ°×ˮƽÉý¸ß£»Í¬Ê±Ö×Áöϸ°ûÒ²»á¸ß±í´ïºÏ³ÉÏËÈÜøԭ¼¤»îÎplasminogen activator£¬PA£©£¬Ôö½øÏËάÂÑ°×Ô­¼°ÏËάÂѰ׵Ľµ½â£¬¹Ê¶øѪÇåÖÐÏËάÂÑ°×½µ½â²úÆ·¸´ºÏÎïˮƽÉý¸ß¡£

ͼƬȪԴ£ºÍøÂç

        ÒÔθ°©ÎªÀý£¬DR-70ÓëCEAµÈ°©Ï¸°û𤸽·Ö×Ó²î±ð£¬ÔÚѪҺÖÐ×ÔÓÉƯ¸¡£¬ÓÚѪÇåÖк¬Á¿×ºñ£¬ÆäÔÚθ°©»¼ÕßѪҺÖеļì³öÑôÐÔÂÊ¿ÉÒÔͨ¹ýͬʱÕÉÁ¿¿ÉÄܱ»ÆäËû²âÊÔËùµÍ¹ÀµÄ¶àÖÖFDPÀ´³äµ±“°©Ö¢µÄÇçÓê±í”¡£

KaplaneMeier curves for overall survival and overall survival of gastric cancer patients who were stratified by DR-70 level.

ͼƬȪԴ£ºHung Y-P, et al., The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients, Journal of the Chinese Medical Association (2018), https://doi.org/10.1016/j.jcma.2018.01.009

Èý¡¢ÐÂÐÍÖ×Áö±ê¼ÇÎïDR-70¼ì²â

        ÎÒÃÇÈ«ÐÂÍƳöÐÂÐÍÖ×Áö±ê¼ÇÎïDR-70£ºÐÂÐÍÖ×Áö±ê¼ÇÎïDR-70¼ì²âÏîÄ¿£¬ÁýÕÖ¶à¸ö¸ß·¢°©ÖÖ£¬¾«×¼¶¨Î»¸ßΣº¦ÈËȺɸ²é¡£

• ÁýÕÖ13´ó¸ß·¢°©ÖÖ

• ¸ßΣº¦ÈËȺ

- ÄêËê40ËêÒÔÉÏ - ÉúÑÄ·½·¨Óдý¸ÄÉÆÈËȺ£ºÎüÑÌ¡¢Òû¾Æ¡¢²»×¢ÖØÌåÓýÄ¥Á¶ - ²¡¶¾»òϸ¾úѬȾ£¬ÈçÒҸΡ¢±û¸Î¡¢HPV¡¢ÓÄÃÅÂݸ˾úµÈ

- ´úлÀàµÄ¼²²¡£¬ÈçÌÇÄò²¡¡¢³¬ÖØ¡¢·ÊÅÖµÈ

- ÇéÐÎÒòËØÓ°Ï죬Èç¿ÕÆøÎÛȾ¡¢Ò»Ð©Óк¦ÎïÖʵĽӴ¥

- Ö°ÒµÏà¹ØµÄ̻¶£¬Èç¾­³£½Ó´¥·Û³¾¡¢ÃºÑÌ¡¢»¯Ñ§ÎïÖʵÈ

• ÏîÄ¿ÓÅÊÆ

? ÎÞ´´

? ¸üÒ×ÍƹãʵÑé

? ¸ßѸËٶȼ°ÌØÒìÐÔ

• Ñù±¾ÒªÇó

ѪÇå

²Î¿¼ÎÄÏ×

[1] Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014;17:26-33.

[2] Hou JX, Yang XQ, Chen C, Jiang Q, Yang GL, Li Y. Screening the gastric cancer related tumor markers from multi-tumor markers protein chip with kappa coefficient and cost-effectiveness analysis. Hepatogastroenterology 2011;58:632-6.

[3] Wu D, Zhou X, Yang G, Xie Y, Hu M, Wu Z, et al. Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. J Immunoassay 1998;19:63-72.

[4] Lin SZ, Chen CC, Lee KC, Tseng CW, Lin HY, Chen YC, et al. DR-70 immunoassay for the surveillance of hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:547-52.